{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:49:15Z","timestamp":1773373755379,"version":"3.50.1"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"unspecified","delay-in-days":168,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC0102"],"award-info":[{"award-number":["CC0102"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC1114"],"award-info":[{"award-number":["CC1114"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC1283"],"award-info":[{"award-number":["CC1283"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2041"],"award-info":[{"award-number":["CC2041"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2060"],"award-info":[{"award-number":["CC2060"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2166"],"award-info":[{"award-number":["CC2166"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2230"],"award-info":[{"award-number":["CC2230"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["CC0102"],"award-info":[{"award-number":["CC0102"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["CC1114"],"award-info":[{"award-number":["CC1114"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["CC1283"],"award-info":[{"award-number":["CC1283"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["CC2041"],"award-info":[{"award-number":["CC2041"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["CC2060"],"award-info":[{"award-number":["CC2060"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["CC2166"],"award-info":[{"award-number":["CC2166"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["CC2230"],"award-info":[{"award-number":["CC2230"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CC0102"],"award-info":[{"award-number":["CC0102"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CC1114"],"award-info":[{"award-number":["CC1114"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CC1283"],"award-info":[{"award-number":["CC1283"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CC2041"],"award-info":[{"award-number":["CC2041"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CC2060"],"award-info":[{"award-number":["CC2060"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CC2166"],"award-info":[{"award-number":["CC2166"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CC2230"],"award-info":[{"award-number":["CC2230"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W005611\/1"],"award-info":[{"award-number":["MR\/W005611\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X006751\/1"],"award-info":[{"award-number":["MR\/X006751\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/Y004205\/1"],"award-info":[{"award-number":["MR\/Y004205\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000381","name":"Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["92"],"award-info":[{"award-number":["92"]}],"id":[{"id":"10.13039\/501100000381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","award":["RP-2017-08-ST2-004"],"award-info":[{"award-number":["RP-2017-08-ST2-004"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,11,9]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>People with multiple sclerosis (pwMS) receiving B-cell depleting disease-modifying therapy (BCD-DMT) are vulnerable to severe COVID-19. Data on vaccine immunogenicity in this patient group are incomplete. In the context of the rapid evolution of SARS-CoV-2 2020\u201322, we compared vaccine responses in pwMS and healthy vaccinated adults (HVA) after three doses of messenger RNA vaccine encoding Ancestral SARS-CoV-2 Spike.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this prospective observational cohort study, we collected serum from 226 pwMS prevaccine and postvaccine and quantified neutralising antibody titres (nAbT) in a high-throughput live virus assay against SARS-CoV-2 Ancestral, Alpha, Delta, Omicron BA.1, BA.2 and BA.5. We compared nAbT in pwMS and HVA, matched by age, sex, vaccine type, number of doses and time since exposure, using Wilcoxon signed-rank and \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      tests. We further investigated nAbT vaccine response in pwMS on BCD-DMTs or non-depleting DMTs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Prior to third vaccination, nAbTs against nearly all variants tested were significantly lower (p&lt;0.05) in pwMS taking BCD therapy than those in HVA or B-cell replete pwMS, and were not significantly boosted following vaccination. In contrast, B-cell replete pwMS versus HVAs exhibited equivalent prevaccination nAbTs against all variants, which were comparably boosted against most variants following vaccination. Consequently, differences in nAbTs against all variants tested were further magnified between B-cell replete and B-cell depleted pwMS post-third vaccination. Across the entire cohort, there were no COVID-19 hospitalisations or deaths. Notably, sera collected prior to the pandemic from pwMS demonstrated pre-existing, pan-coronavirus neutralising activity against seasonal HCoV-OC43 and SARS-CoV-2 variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PwMS taking BCD therapy have limited antibody boosting following repeated COVID-19 vaccination. However, the absence of severe outcomes in pwMS, despite reduced immunogenicity, suggests a lower threshold for effective protection than previously reported. These findings support more nuanced risk stratification in clinical policy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001210","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:15:15Z","timestamp":1765962915000},"page":"e001210","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity of three-dose COVID-19 vaccines in people living with multiple sclerosis"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct04750356","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-3389","authenticated-orcid":false,"given":"Marianne J","family":"Shawe-Taylor","sequence":"first","affiliation":[{"name":"The Francis Crick Institute, London, UK"},{"name":"National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, UCLH, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Greenwood","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"He","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"},{"name":"Department of Neuroscience, Monash University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Hobbs","sequence":"additional","affiliation":[{"name":"COVID Surveillance Unit, The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Dowgier","sequence":"additional","affiliation":[{"name":"COVID Surveillance Unit, The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Penn","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Sanderson","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phoebe","family":"Stevenson-Leggett","sequence":"additional","affiliation":[{"name":"COVID Surveillance Unit, The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Bazire","sequence":"additional","affiliation":[{"name":"COVID Surveillance Unit, The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Harvey","sequence":"additional","affiliation":[{"name":"Worldwide Influenza Centre, The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Champsas","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suraiya","family":"Sharmin","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuriti","family":"Aojula","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Bianchi","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarmad","family":"Al-Araji","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Hacohen","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charmaine","family":"Yam","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suraya","family":"Mohamud","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronja","family":"Christensen","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Crick COVID Serology Pipeline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Legacy Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Libri","sequence":"additional","affiliation":[{"name":"National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Kassiotis","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"},{"name":"Department of Infectious Disease, St Mary\u2019s Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Gamblin","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Lewis","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"},{"name":"Worldwide Influenza Centre, The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[{"name":"National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, UCLH, London, UK"},{"name":"UCL, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"},{"name":"University College London Cancer Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Gandhi","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"},{"name":"UCL, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bauer","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"},{"name":"Genotype-to-Phenotype 2 Consortium, The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Wu","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"},{"name":"COVID Surveillance Unit, The Francis Crick Institute, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Carr","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"},{"name":"UCL, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Wall","sequence":"additional","affiliation":[{"name":"The Francis Crick Institute, London, UK"},{"name":"National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, UCLH, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-1367","authenticated-orcid":false,"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery, London, UK"},{"name":"Neurology and Neuroscience Biomedical Research Centre, UCL, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"2025121701151369000_7.2.e001210.1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001066"},{"key":"2025121701151369000_7.2.e001210.2","doi-asserted-by":"crossref","first-page":"104701","DOI":"10.1016\/j.ebiom.2023.104701","article-title":"B cell depletion therapy does not resolve chronic active multiple sclerosis lesions","volume":"94","author":"Maggi","year":"2023","journal-title":"eBioMedicine"},{"key":"2025121701151369000_7.2.e001210.3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14712598.2019.1568407","article-title":"B cell depletion in the treatment of multiple sclerosis","volume":"19","author":"Myhr","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2025121701151369000_7.2.e001210.4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458520943791","article-title":"Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient","volume":"26","author":"Wurm","year":"2020","journal-title":"Mult Scler"},{"key":"2025121701151369000_7.2.e001210.5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4137\/PMC.S13213","article-title":"Multiple sclerosis: overview of disease-modifying agents","volume":"6","author":"Finkelsztejn","year":"2014","journal-title":"Perspect Medicin Chem"},{"key":"2025121701151369000_7.2.e001210.6","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26251"},{"key":"2025121701151369000_7.2.e001210.7","doi-asserted-by":"crossref","unstructured":"Bar-Or A , Calkwood JC , Chognot C , et al . Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. Neurology (ECronicon) 2020;95. doi:10.1212\/WNL.0000000000010380","DOI":"10.1212\/WNL.0000000000010380"},{"key":"2025121701151369000_7.2.e001210.8","unstructured":"GOV.UK . Joint committee on vaccination and immunisation: advice on priority groups for covid-19 vaccination. 2020. Available: https:\/\/www.gov.uk\/government\/publications\/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020\/joint-committee-on-vaccination-and-immunisation-advice-on-priority-groups-for-covid-19-vaccination-30-december-2020"},{"key":"2025121701151369000_7.2.e001210.9","unstructured":"5 supporting information on risk factors for progression to severe COVID-19, Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19, guidance. NICE. n.d. Available: https:\/\/paperpile.com\/b\/n5oKEy\/dTNIC"},{"key":"2025121701151369000_7.2.e001210.10","doi-asserted-by":"crossref","first-page":"103155","DOI":"10.1016\/j.msard.2021.103155","article-title":"COVID-19 vaccines and multiple sclerosis disease-modifying therapies","volume":"53","author":"Giovannoni","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2025121701151369000_7.2.e001210.11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/diseases12020033","article-title":"A Descriptive, Retrospective Analysis of COVID-19 Passive Antibody Therapy and Its Effects on Morbidity and Mortality in Patients Receiving B-Cell-Depleting Therapies","volume":"12","author":"Gentile","year":"2024","journal-title":"Diseases"},{"key":"2025121701151369000_7.2.e001210.12","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1007\/s12325-021-01761-3","article-title":"Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era","volume":"38","author":"Coyle","year":"2021","journal-title":"Adv Ther"},{"key":"2025121701151369000_7.2.e001210.13","doi-asserted-by":"crossref","first-page":"104548","DOI":"10.1016\/j.msard.2023.104548","article-title":"Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study","volume":"71","author":"Barzegar","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2025121701151369000_7.2.e001210.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11237-1"},{"key":"2025121701151369000_7.2.e001210.15","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/acn3.51628","article-title":"Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review\/meta-analysis","volume":"9","author":"Gombolay","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"2025121701151369000_7.2.e001210.16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(24)00316-7","article-title":"Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign","volume":"403","author":"Shawe-Taylor","year":"2024","journal-title":"Lancet"},{"key":"2025121701151369000_7.2.e001210.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00289-X"},{"key":"2025121701151369000_7.2.e001210.18","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","article-title":"Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination","volume":"397","author":"Wall","year":"2021","journal-title":"The Lancet"},{"key":"2025121701151369000_7.2.e001210.19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.75228","article-title":"Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike","volume":"11","author":"Crowley","year":"2022","journal-title":"Elife"},{"key":"2025121701151369000_7.2.e001210.20","unstructured":"WHO\/BS\/2022.2427: establishment of the 2nd WHO international standard for anti-SARS-CoV-2 immunoglobulin and reference panel for antibodies to SARS-CoV-2 variants of concern. n.d. Available: https:\/\/www.who.int\/publications\/m\/item\/who-bs-2022.2427"},{"key":"2025121701151369000_7.2.e001210.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-076892","article-title":"Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis","volume":"13","author":"Rahman","year":"2023","journal-title":"BMJ Open"},{"key":"2025121701151369000_7.2.e001210.22","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2665-9913(24)00065-1","article-title":"Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"6","author":"Goodyear","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025121701151369000_7.2.e001210.23","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12175460","article-title":"COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece","volume":"12","author":"Bakirtzis","year":"2023","journal-title":"J Clin Med"},{"key":"2025121701151369000_7.2.e001210.24","doi-asserted-by":"publisher","DOI":"10.3201\/eid2902.221422"},{"key":"2025121701151369000_7.2.e001210.25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpt.3069","article-title":"Neutralizing Antibody Levels as a Correlate of Protection Against SARS-CoV-2 Infection: A Modeling Analysis","volume":"115","author":"Lingas","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2025121701151369000_7.2.e001210.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266852","article-title":"Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review","volume":"17","author":"Perry","year":"2022","journal-title":"PLoS One"},{"key":"2025121701151369000_7.2.e001210.27","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211012835"},{"key":"2025121701151369000_7.2.e001210.28","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaneurol.2021.3609","article-title":"Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis","volume":"78","author":"Disanto","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025121701151369000_7.2.e001210.29","doi-asserted-by":"crossref","first-page":"104486","DOI":"10.1016\/j.msard.2022.104486","article-title":"Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy","volume":"70","author":"Katz Sand","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2025121701151369000_7.2.e001210.30","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1111\/ene.15925","article-title":"Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization","volume":"30","author":"Louapre","year":"2023","journal-title":"Eur J Neurol"},{"key":"2025121701151369000_7.2.e001210.31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1205879","article-title":"Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis","volume":"14","author":"Maglione","year":"2023","journal-title":"Front Immunol"},{"key":"2025121701151369000_7.2.e001210.32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jamaneurol.2021.5109","article-title":"Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination","volume":"79","author":"K\u00f6nig","year":"2022","journal-title":"JAMA Neurol"},{"key":"2025121701151369000_7.2.e001210.33","doi-asserted-by":"crossref","first-page":"102704","DOI":"10.1016\/j.msard.2020.102704","article-title":"Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness","volume":"48","author":"Barun","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2025121701151369000_7.2.e001210.34","unstructured":"Shielding behavioural survey (SBS) QMI. n.d. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/healthcaresystem\/methodologies\/shieldingbehaviouralsurveysbsqmi"},{"key":"2025121701151369000_7.2.e001210.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104042","article-title":"Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy","volume":"80","author":"Sormani","year":"2022","journal-title":"eBioMedicine"},{"key":"2025121701151369000_7.2.e001210.36","unstructured":"CovSPECTRUM. n.d. Available: https:\/\/cov-spectrum.org\/explore\/United%20Kingdom\/AllSamples\/Past6M"},{"key":"2025121701151369000_7.2.e001210.37","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s43018-021-00275-9","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat Cancer"},{"key":"2025121701151369000_7.2.e001210.38","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/jmv.27644","article-title":"Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studies","volume":"94","author":"Petrelli","year":"2022","journal-title":"J Med Virol"},{"key":"2025121701151369000_7.2.e001210.39","unstructured":"Care S . First UK cases of omicron variant identified. GOVUK; 2021. Available: https:\/\/www.gov.uk\/government\/news\/first-uk-cases-of-omicron-variant-identified"},{"key":"2025121701151369000_7.2.e001210.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04432-7"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:15:22Z","timestamp":1765962922000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12,16]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjno-2025-001210"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001210","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}